David S Russell
Overview
Explore the profile of David S Russell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
2718
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Evidence for alpha-synuclein aggregation in older individuals with hyposmia: a cross-sectional study
Marek K, Russell D, Concha-Marambio L, Choi S, Jennings D, Brumm M, et al.
EBioMedicine
. 2025 Feb;
112:105567.
PMID: 39893720
Background: Synuclein pathology in neurodegenerative diseases, such as Parkinson's disease (PD) and Dementia with Lewy bodies (DLB), begins years before motor or cognitive symptoms arise. Alpha-Synuclein seed amplification assays (α-syn...
2.
Terry-Lorenzo R, Albrecht D, Crouch S, Wong R, Loewen G, Giri N, et al.
Neuropsychopharmacology
. 2025 Jan;
50(4):719.
PMID: 39843851
No abstract available.
3.
Terry-Lorenzo R, Albrecht D, Crouch S, Wong R, Loewen G, Giri N, et al.
Neuropsychopharmacology
. 2025 Jan;
PMID: 39757283
Positron emission tomography (PET) is frequently used to obtain target occupancy (%TO) of central nervous system (CNS) drug candidates during clinical development. Obtaining %TO with PET can be particularly powerful...
4.
Kielbasa W, Goldsmith P, Donnelly K, Nuthall H, Shcherbinin S, Fleisher A, et al.
Alzheimers Dement (N Y)
. 2025 Jan;
10(4):e70020.
PMID: 39748851
Introduction: The aggregation and spread of hyperphosphorylated, pathological tau in the human brain is hypothesized to play a key role in Alzheimer's disease (AD) as well as other neurogenerative tauopathies....
5.
Olafson E, Tonietto M, Klein G, Teng E, Stephens A, Russell D, et al.
J Nucl Med
. 2025 Jan;
66(2):277-285.
PMID: 39746756
Alzheimer disease (AD) is characterized by the accumulation of tau neurofibrillary tangles that can be labeled with PET tracers. Multiple tau PET tracers have been used in clinical studies, including...
6.
Wise A, Ortega R, Raymond D, Cervera A, Thorn E, Leaver K, et al.
Front Neurol
. 2024 Aug;
15:1450654.
PMID: 39175765
Background: variants have been associated with immune dysregulation as well as immune-related disorders such as IBD. A possible relationship between multiple sclerosis (MS) and PD has also been suggested. Further,...
7.
Smith R, Capotosti F, Schain M, Ohlsson T, Vokali E, Molette J, et al.
Nat Commun
. 2023 Oct;
14(1):6750.
PMID: 37891183
A positron emission tomography (PET) tracer detecting α-synuclein pathology will improve the diagnosis, and ultimately the treatment of α-synuclein-related diseases. Here we show that the PET ligand, [F]ACI-12589, displays good...
8.
Pagano G, Taylor K, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, et al.
N Engl J Med
. 2022 Aug;
387(5):421-432.
PMID: 35921451
Background: Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson's disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on Parkinson's disease....
9.
Brasic J, Goodman J, Nandi A, Russell D, Jennings D, Barret O, et al.
Brain Sci
. 2022 Mar;
12(3).
PMID: 35326270
Multiple lines of evidence suggest that a deficiency of Fragile X Mental Retardation Protein (FMRP) mediates dysfunction of the metabotropic glutamate receptor subtype 5 (mGluR5) in the pathogenesis of fragile...
10.
Song M, Beyer L, Kaiser L, Barthel H, van Eimeren T, Marek K, et al.
J Cereb Blood Flow Metab
. 2021 May;
41(11):2957-2972.
PMID: 34044665
The novel tau-PET tracer [F]PI-2620 detects the 3/4-repeat-(R)-tauopathy Alzheimer's disease (AD) and the 4R-tauopathies corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). We determined whether [F]PI-2620 binding characteristics deriving from...